Neurocrine Biosciences Halts Development of Experimental Drug for Schizophrenia
London: Neurocrine Biosciences announced on Thursday that it will cease the development of its experimental drug, aimed at enhancing cognitive function in patients with schizophrenia, after it failed to meet the primary goal in a mid-stage trial.
The company stated that the drug, Luvadaxistat, did not replicate the results from a previous mid-stage trial that showed improved cognitive performance. This was due to significant variability in cognitive measures across patients and potential imbalances in baseline characteristics.
In the previous study, Luvadaxistat failed to meet the main goal of reducing negative symptoms of schizophrenia, but it did achieve the secondary goal of improving cognitive performance.
Neurocrine Biosciences will now focus its resources on the late-stage development of its other schizophrenia and depression drug candidates.
Shares of the company fell 2.5% in extended trading.
Last month, the company reported that its other schizophrenia drug, NBI-1117568, helped reduce the severity of symptoms in a mid-stage trial, but there were concerns about replicating the benefits in larger trials.
[Article Published on Sep 13, 2024 at 07:05 AM IST]
[Category: Most Read]
[Comment Section]
[Subscription Section]
Join the community of 2M+ industry professionals. Subscribe to our newsletter to get latest insights & analysis.
Reference : https://health.economictimes.indiatimes.com/news/pharma/pharma-industry/neurocrine-halts-development-of-schizophrenia-drug-as-trial-fails/113306946
